Cancer type Study or subgroup Study type CIK group vs control group (n) CIK cells per infusion(×109) PFS%  (month/year) OS%  (month /year) MPFS(month) MOS(month)
Hepato -cellular carcinoma Hao MZ 2010 [96] Retrospective 72 vs 74 10-50 6m/1y/2y: 72.2/40.4/25.3 vs 34.8/7.7/2.6(P<0.001) 6m/1y/2y: 90.3/71.9/62.4 vs74.6/62.8/18.8(P<0.001) 31 vs 10(P<0.001)
Pan K 2013 [97] Retrospective 204 vs 206 10-50 1y/2y/3y/4y/5y: 93.6/83.3/76.6/71.1 vs 84.0/69.2/61.6/56.9/50.2(P=0.0007)
Huang ZM 2013 [98] Retrospective 85 vs 89 Unclear 1y/3y/5y:54.7/28.7/19.1 vs 34.7/7.0/0.0(P<0.001) 1y/3y/5y/10y: 83.5/62.7/44.0/12.6 vs 76.4/40.4/23.7/0.0(P<0.05) 17 vs10(P<0.001) 56 vs 31(P=0.023)
Yu X 2014 [99] Phase II 66 vs 66 7.2-12.1 1y/2y/3y:74.2/53.0/42.4 vs50.0/30.3/24.2(P<0.05)
Cui J 2014 [100] Retrospective 30 vs 32 1.0-2.0 1y/2y: 100/100 vs 92.6/76.6(P<0.05) Undefined vs 12
Lee JH 2015 [101] Phase III 115 vs 115 6.4±2.1 44.0 vs 30.0(P=0.010)
Pan QZ 2015 [102] Retrospective 511 vs 520 10-15 1y/3y/5y:54.0/37.8/33.0 vs 49.4/29.9/25.9(P=0.014) 1y/3y/5y:82.4/60.0/47.5 vs 74.4/46.6/38.1(P=0.001) 16 vs 12(P=0.014) 41 vs 28(P=0.001)
Gastric cancer Jiang JT 2010 [103] Retrospective 75 vs 81 1 2y/5y:73.5/40.4 vs 52.6/23.9(P<0.05) 49 vs 27(P=0.007)
Shi L 2012 [104] Retrospective 74 vs 77 1 3y/5y:47.3/28.3 vs 36.4/10.4(P=0.044) 3y/5y: 67.6/32.4 vs 54.5/23.4(P=0.071)
Zhao H 2013 [105] Retrospective 53 vs 112 5 3y: 54.7 vs 33.0(P=0.076)5y: 49.1 vs 24.1(P=0.026) 3y: 62.3 vs 46.4(P=0.201)5y: 56.6 vs 26.8(P=0.014) 36 vs 23(P=0.028)
Liu H 2013 [106] Retrospective 51 vs 47 1 1y/2y/3y:98.0/92.2/72.5 vs 93.6/78.7/59.6(P<0.005)
Renal cell carcinoma Liu L 2012 [107] Phase II 74 vs 74 7.6-11.4 3y: 18 vs 12(P=0.031) 3y: 61 vs 23(P<0.001) 12 vs 8(P=0.024) 46 vs 19(P<0.001)
Wang ZX 2014 [108] Meta-analysis 156 vs 144 1y: 94 vs 80(P=0.0002)2y: 81 vs 63(P<0.0001)
Lung cancer Li R 2012 [109] Phase II 87 vs 87 13.07±1.37 3y: 39 vs 32(P=0.050)* 3y: 61 vs 39(P=0.001) 24 vs 12(P=0.028) 48 vs 18(P=0.001)
Zhang J 2015 [110] Retrospective 60 vs 60 Unclear 3y/5y: 44.7/26.8 vs 27/20(P=0.014) 3y/5y:74/62 vs 52/37(P=0.006) 24 vs 14(P=0.014) 72 vs 44(P=0.006)
Colorectal carcinoma Zhu Y 2013 [111] Retrospective 21 vs 75 3 1y/2y: 89.47/59.65 vs 75.88/29.3(P=0.034)
Zhang J 2014 [112] Retrospective 30 vs 30 Unclear 25.8 vs 12.0(P=0.001) 41.3 vs 30.8(P=0.037)
Ovarian cancer Liu J 2014 [113] Retrospective 46 vs 46 11.82±1.61 1y/2y/3y: 95.7/78.3/52.8 vs 91.3/45.7/21.7(P=0.004) 3y: 86.1 vs 83.3(P=0.289) 37.7 vs 22.2(P=0.004) 61.5 vs 55.9(P=0.289)
Breast cancer Pan K 2014 [114] Retrospective 45 vs 45 8.7-12.0 1y/2y/3y/4y:97.7/90.1/83.4/75.2 vs 88.9/64.4/62.1/56.4(P=0.0382) 1y/2y/3y/4y: 100/100/96.7/92.4 vs 95.6/88.6/76.3/72.7(P=0.0046)
Nasopharyngeal carcinoma Li JJ 2012 [115] Randomly 30 vs 30 1.25-18.2 1y/2y:24/12 vs 23/5(P=0.0234) 1y/2y:27/21 vs 25/15(P=0.1347) 26.93 vs 19.90(P=0.0234) Undefined vs 23
Melanoma Han GL 2012 [116] Retrospective 38 vs 114 11.57±2.45 1y: 86.8 vs 74.6(P=0.097)3y: 76.3 vs 46.5(P=0.001)y: 71.1 vs 43.9(P=0.004) Undefined vs 20.1(P=0.004)
Pancreatic cancer Wang M 2013 [117] Randomly 29 vs 29 Unclear 2.9 vs 2.5 (P=0.037) 6.6 vs 6.1(P=0.09)
VS: versus; PFS: Progression Free Survival; OS: Overall Survival; MPFS: Median Progression Free Survival; MOS: Median Overall Survival; Unclear: not mentioned in the article; Undefined: There are still alive patients until follow-up due date; *: Different p value in Early (I-IIIA) stage group (P=0.259) and Advanced (IIIB-IV) stage group (P<0.001)
Table 6: The effectiveness of CIK cell therapy in clinical trials.